Antibody Therapeutics 2025年首期回顾：抗体药物研发新趋势全景呈现
2025年11月6日
由华人抗体协会（ChAbS）旗下期刊 Antibody Therapeutics 推出的 Volume 8, Issue 1（2025年首期） 已正式发布回顾！本期汇集了来自全球科研团队的原创研究与深度综述，涵盖双特异性抗体、CAR载体质控、蛋白药物冻干、系统性红斑狼疮抗体疗法等前沿领域，全面呈现了抗体药物研发的最新突破与应用趋势，为科研人员提供了宝贵的前沿参考。
本期亮点速览
创新技术平台：Hybridoma-to-Phage-to-Yeast (H2PtY) 平台助力发现新型PD-1/PD-L1双抗 https://doi.org/10.1093/abt/tbae027
人源化抗体新进展：首次报道可用于基础研究与治疗的抗CD11d单抗 https://doi.org/10.1093/abt/tbae031
CAR载体质控创新：生物发光报告系统提升CAR-LV效价评估效率 https://doi.org/10.1093/abt/tbae032
结构改造策略：精确定义CD30表位实现由激动型到拮抗型抗体的转化https://doi.org/10.1093/abt/tbaf002
冻干蛋白药物开发指南：从配方到工艺的实用经验总结https://doi.org/10.1093/abt/tbae030，该文作者来自Regeneron,该文自今年1月上线后已被引用10余次。
系统性红斑狼疮抗体治疗回顾：前沿管线与未来5–10年潜力药物 https://doi.org/10.1093/abt/tbae033
近红外光免疫治疗综述：该文作者来自哈佛大学，该文对创新技术近红外光免疫治疗从机制到临床应用进行了全面展望。
阅读本期内容：https://academic.oup.com/abt/issue/8/1📚 Antibody Therapeutics 致力于搭建全球抗体药物研发的交流平台，关注从基础研究到临床转化的全链条创新。欢迎广大科研与产业界读者关注、投稿与分享！
Volume 8, Issue 1, January 2025
1. Discovery of a common light chain bispecific antibody targeting PD-1 and PD-L1 by Hybridoma-to-Phage-to-Yeast (H2PtY) platform.
Corresponding author: Sujun Deng, Biologics Innovation Institute, Shanghai Jemincare Pharmaceutical Co., Ltd.
Antibody Therapeutics, Volume 8, Issue 1, January 2025, Pages 1 12,
https://doi.org/10.1093/abt/tbae027
2. Humanized anti-CD11d monoclonal antibodies suitable for basic research and therapeutic applications
Corresponding author: Gregory A Dekaban, University of Western Ontario
Antibody Therapeutics, Volume 8, Issue 1, January 2025, Pages 26–39, https://doi.org/10.1093/abt/tbae031
3. A bioluminescent reporter bioassay for in-process assessment of chimeric antigen receptor lentiviral vector potency
Corresponding author: Mei Cong, Promega Corp.
Antibody Therapeutics, Volume 8, Issue 1, January 2025, Pages 40–46, https://doi.org/10.1093/abt/tbae032
4. Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule
Corresponding author: Hiroki Akiba, Kyoto University.
Antibody Therapeutics, Volume 8, Issue 1, January 2025, Pages 56–67, https://doi.org/10.1093/abt/tbaf002
5. Practical advice in the development of a lyophilized protein drug product
Corresponding author: Xiaolin (Charlie) Tang, Regeneron Pharmaceuticals Inc.
Antibody Therapeutics, Volume 8, Issue 1, January 2025, Pages 13–25, https://doi.org/10.1093/abt/tbae030
6. Current use and development of monoclonal antibodies for the treatment of systemic lupus erythematosus: a review
Corresponding author: Alexander Blagov, Institute of General Pathology and Pathophysiology.
Antibody Therapeutics, Volume 8, Issue 1, January 2025, Pages 47–55, https://doi.org/10.1093/abt/tbae033
7. Near-infrared photoimmunotherapy: mechanisms, applications, and future perspectives in cancer research
Corresponding author: Mohammad A Saad , Massachusetts General Hospital and Harvard Medical School.
Antibody Therapeutics, Volume 8, Issue 1, January 2025, Pages 68–85, https://doi.org/10.1093/abt/tbaf001
期刊简介《Antibody Therapeutics》是华人抗体协会（ChAbS）的旗下期刊，由牛津大学出版社（Oxford University Press）出版。作为一本同行评审的开放获取期刊，Antibody Therapeutics 为全球科学界提供了一个平台，用于发表治疗性抗体在发现、研究、开发及相关方法学方面的最新进展与挑战。该期刊已被ESCI（影响因子=4.5）、Scopus（CiteScore=8.4）及PubMed Central等主要文献数据库收录。
期刊官网：https://academic.oup.com/abt （点击文末阅读原文直达官网）
期刊Linkedin: https://www.linkedin.com/company/antibody-therapeutics
华人抗体协会华人抗体协会是一个非营利、非政府的公益性组织，是第一个也是目前唯一一个全球性华人抗体专业组织。协会侧重关注治疗性抗体，并致力于创建一个全球性平台，以促进在治疗性抗体研发，生产以及商业化等领域的合作与交流。关于协会更多介绍请参阅：华人抗体协会简介与发展简史
华人抗体协会与牛津大学出版社合作，出版同行评审英文专业期刊: Antibody Therapeutics。
华人抗体协会网站：
www.chabs.org
Follow us at LinkedIn:
www.linkedin.com/company/chabs-华人抗体协会
编辑：刘玉娥审阅：王守业转载本文请联系原作者获取授权，同时请注明本文来自刘玉娥科学网博客。
链接地址：https://wap.sciencenet.cn/blog-3592244-1509216.html?mobile=1
收藏
